References
American Cancer Society. (2011a). Cancer facts and figures. Retrieved from http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011
American Cancer Society. (2011b). Leukemia—Chronic myeloid (myelogenous). Retrieved from http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-what-is-c-m-l
Bauer, S., & Romvari, E. (2009). Treatment of chronic myeloid leukemia following imatinib resistance: A nursing guide to second-line treatment options. Clinical Journal of Oncology Nursing, 13, 523–534.
Bristol-Myers Squibb. (2011). Important safety information about Sprycel®. Retrieved from http://www.sprycel.com
Deininger, M.W., Goldman, J.M., & Melo, J.V. (2000). The molecular biology of chronic myeloid leukemia. Blood, 96, 3343–3356. Retrieved from http://bloodjournal.hematologylibrary.org/content/96/10/3343.full?ijkey=54817b4679305a081bc02c488eaabc66f4d64e7b&keytype2=tf_ipsecsha
Faderl, S., Talpaz, M., Estrov, Z., O’Brien, S., Kurzrock, R., & Kantarjian, H.M. (1999). The biology of chronic myeloid leukemia. New England Journal of Medicine, 341, 164–172.
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O’Brien, S., Wassmann, B., Tanaka, C., . . . Ottmann, O.G. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome positive ALL. New England Journal of Medicine, 354, 2542–2551.
National Cancer Institute. (2011a). Chronic myelogenous leukemia treatment PDQ. Retrieved from http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional/page3
National Cancer Institute. (2011b). General information about chronic myelogenous leukemia. Retrieved from http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional/page1
National Comprehensive Cancer Network. (2011). Chronic myelogenous leukemia. Clinical practice Guidelines in Oncology Version 2.2012. Retrieved from www.nccn.org
Novartis. (2011a). Gleevec® drug prescription important safety information. Retrieved from http://www.gleevec.com/safety-information.jsp?site=PU025155&irmasrc=GLIWB0082&source=01030
Novartis. (2011b). Tasigna® prescribing information. Retrieved from http://www.us.tasigna.com/health-care-professional/prescribing-information.jsp?site=PU005215&irmasrc=AM7WB0039&source=01030
Onida, F., Ball, G., Katarjian, H.M, Smith, T.L., Galssman, A., Albitar, M., . . . Beran, M. (2002). Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer, 95, 1673–1684. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12365015?dopt=Abstract
Saglio, G., Kim, D., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., . . . Kantarjian, H.M. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362, 2251–2259.